BBS-BIOACTIVE BONE SUBSTITUTES OYJ Financials BBS-Bioactive Bone Substitutes Oyj
Equities
BONEH
FI4000260583
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.392 EUR | -0.25% |
|
+12.00% | -19.84% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15.29 | 11.28 | 9.436 | 7.584 | - | - |
| Enterprise Value (EV) 1 | 15.29 | 15.49 | 12.97 | 14.28 | 19.08 | 7.584 |
| P/E ratio | -5.21 x | -3.41 x | -2.72 x | -2.31 x | -1.79 x | -1.71 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 12.6 x | 3.79 x |
| EV / Revenue | - | - | - | - | 31.8 x | 3.79 x |
| EV / EBITDA | - | -5.68 x | -4.12 x | -4.76 x | -5.45 x | -2.11 x |
| EV / FCF | - | -5.35 x | -4.44 x | -4.61 x | -4.15 x | -1.55 x |
| FCF Yield | - | -18.7% | -22.5% | -21.7% | -24.1% | -64.6% |
| Price to Book | - | - | 1.88 x | 4.37 x | -3.02 x | - |
| Nbr of stocks (in thousands) | 6,982 | 9,437 | 19,297 | 19,297 | - | - |
| Reference price 2 | 2.190 | 1.195 | 0.4890 | 0.3930 | 0.3930 | 0.3930 |
| Announcement Date | 2/24/22 | 2/24/23 | 2/26/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.6 | 2 |
| EBITDA 1 | - | -2.726 | -3.15 | -3 | -3.5 | -3.6 |
| EBIT 1 | - | -2.952 | -3.367 | -3.2 | -4 | -4.2 |
| Operating Margin | - | - | - | - | -666.67% | -210% |
| Earnings before Tax (EBT) 1 | - | -3.093 | -3.484 | -3.3 | -4.3 | -4.4 |
| Net income 1 | -2.771 | -3.093 | -3.484 | -3.3 | -4.3 | -4.4 |
| Net margin | - | - | - | - | -716.67% | -220% |
| EPS 2 | -0.4200 | -0.3500 | -0.1800 | -0.1700 | -0.2200 | -0.2300 |
| Free Cash Flow 1 | - | -2.894 | -2.923 | -3.1 | -4.6 | -4.9 |
| FCF margin | - | - | - | - | -766.67% | -245% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 2/24/23 | 2/26/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.2 | 0.4 |
| EBITDA 1 | - | -1.359 | - | -1.683 | -1.5 | -1.5 | -1.9 | -2.1 |
| EBIT 1 | - | -1.471 | - | -1.792 | -1.6 | -1.6 | -1.9 | -2.1 |
| Operating Margin | - | - | - | - | - | - | -950% | -525% |
| Earnings before Tax (EBT) 1 | - | -1.416 | - | -1.842 | -1.7 | -1.7 | -1.9 | -2.1 |
| Net income 1 | -1.676 | -1.416 | -1.642 | -1.842 | -1.7 | -1.7 | -1.9 | -2.1 |
| Net margin | - | - | - | - | - | - | -950% | -525% |
| EPS 2 | -0.2400 | -0.1400 | -0.1700 | -0.1000 | -0.0900 | -0.0900 | -0.1000 | -0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/25/22 | 2/24/23 | 8/25/23 | 2/26/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.22 | 3.53 | 6.7 | 11.5 | - |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -1.546 x | -1.122 x | -2.233 x | -3.286 x | - |
| Free Cash Flow 1 | - | -2.89 | -2.92 | -3.1 | -4.6 | -4.9 |
| ROE (net income / shareholders' equity) | - | -78.2% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 0.2600 | 0.0900 | -0.1300 | - |
| Cash Flow per Share 2 | - | -0.3400 | -0.1500 | -0.1500 | -0.1900 | - |
| Capex 1 | - | 0.08 | - | 0.1 | 0.9 | 1 |
| Capex / Sales | - | - | - | - | 150% | 50% |
| Announcement Date | 2/24/22 | 2/24/23 | 2/26/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
0.393
EUR
Average target price
0.4
EUR
Spread / Average Target
+1.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.31% | 8.2M | |
| +8.29% | 124B | |
| -4.82% | 11.17B | |
| +4.83% | 9.17B | |
| -22.04% | 4.71B | |
| +8.39% | 3.44B | |
| -6.28% | 2.88B | |
| -10.23% | 2.11B | |
| -5.99% | 2.09B | |
| -22.62% | 1.8B |
- Stock Market
- Equities
- BONEH Stock
- Financials BBS-Bioactive Bone Substitutes Oyj